US-based genetic analysis firm OpGen has entered into an agreement with Hitachi High-Technologies for the development of human chromosome mapping analytical service for clinical research applications. The new service, which will be a ...
Tags: Analytical Service, OpGen, Hitachi
Genia Technologies in consortium with Columbia University and Harvard Medical School, has secured a three-year $5.25m grant from the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), to develop ...
Tags: Health, Medicine, DNA Sequencing Platform
US-based genomics company BioNano Genomics has launched Irys System for genome mapping in the region of European Union (EU). The Irys benchtop instrument is fully automated and uses the IrysChip to uncoil and confine long DNA molecules in ...
Tags: Bionano, Irys System
China-based BGI-Shenzhen, through its subsidiary Beta Acquisition, has purchased Complete Genomics, a provider of whole human genome sequencing services. US-based Complete's products include advanced informatics and analysis systems that ...
Belgium-based biopharmaceutical company UCB has signed a research deal with ConfometRx for the discovery of new drugs. Under the deal, UCB and ConfometRx will leverage structural biology to gain insight into G-protein coupled receptor ...
Tags: drug discovery, biopharmaceutical, UCB
Agilent Technologies Inc and SRI International have announced they have signed a licensing agreement to offer laboratory research customers a package that combines Agilent’s latest release of GeneSpring GX, GeneSpring NGS, Mass ...
Agilent Technologies Inc and WiCell have announced that WiCell is now offering comparative genomic hybridisation plus single nucleotide polymorphism microarray analysis using the Agilent SurePrint G3 Human Genome CGH+SNP Microarray. ...
Tags: Collaboration, Agilent Technologies, WiCell, CGH+SNP Microarray
Cloud computing will move supercomputers out of the research labs and into c, it was claimed this week. Dial-up supercomputing services are making it possible for smaller companies to analyse vast quantities of data, run engineering ...
Harvard researchers have been able to use sequencing technology to store 70 billion copies of a yet-unpublished book in DNA binary code. The results of the project by researchers at Harvard University's Wyss Institute for Biologically ...
Tags: Harvard, sequencing technology, DNA binary code, 70 billion books
Affymetrix has launched SensationPlus FFPE Amplification and 3' IVT Labeling Kit (SensationPlus FFPE Reagent Kit). SensationPlus FFPE Reagent Kit, which comprises RNA amplification and labeling modules, is designed to enable gene ...
Tags: FFPE Reagent Kit, 3'IVT Labeling Kit, clinical technology
Microsoft's most significant update to Windows Azure takes the cloud platform to a different level. Rather than focus on Windows applications and bridging the gap between in-house and cloud-based IT, Microsoft is now offering Azure as ...
Tags: Microsoft, Azure, cloud infrastructure
The US Food and Drug Administration (FDA) has cleared Sigma-Tau Pharmaceuticals' topical ophthalmic therapeutic to treat corneal cystine crystals in cystinosis patients. The CYSTARAN 0.44% solution, which is developed in collaboration ...
Research-based pharmaceutical and healthcare company GlaxoSmithKline (GSK) has completed acquisition of Human Genome Sciences (HGS) for $3.6bn on an equity basis, or approximately $3 billion net of cash and debt. With the acquisition, all ...
Tags: GSK, GlaxoSmithKline, Human Genome Sciences
Human Genome Sciences (HGS) has rejected $2.6bn (£1.6bn) takeover bid offered by GlaxoSmithKline (GSK). GSK offered $13 per share, which is 81% premium to HGS closing price on 18 April 2012, of $7.17 per share. HGS has partnered ...
Tags: HGS, GSK, GlaxoSmithKline
The Anti-Infective Drugs Advisory Committee to the US Food and Drug Administration (FDA) has supported the clinical benefit of GlaxoSmithKline's raxibacumab to treat inhalational anthrax. In addition, the committee also favoured the ...
Tags: The Anti-Infective Drugs, raxibacumab anti-toxin development programme